TLSI - NASDAQ
TriSalus Life Sciences, Inc.
$3.29
+3.0%TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
At a Glance
Live Snapshottlsi
Other Non-Cash Items
Last Annual Value
9.39M
3-Year CAGR
-7%
5-Year CAGR
73%
10-Year CAGR
32%
TriSalus Life Sciences, Inc. Competitors Analysis of Other Non-Cash Items
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TriSalus Life Sciences, Inc. NASDAQ:TLSI | 9.39M | 15.1% | 10.5% | N/A | |
 MaxCyte, Inc. NASDAQ:MXCT | 1.99M | N/A | 24.5% | 37.6% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | -237.00K | N/A | N/A | N/A | |
 Sight Sciences, Inc. NASDAQ:SGHT | 1.59M | -11.7% | 4.5% | N/A | |
 Hyperfine, Inc. NASDAQ:HYPR | -677.00K | N/A | N/A | N/A | |
 AVITA Medical, Inc. NASDAQ:RCEL | 2.40M | N/A | 9.3% | N/A | |
 Rapid Micro Biosystems, Inc. NASDAQ:RPID | 2.71M | N/A | -34.9% | N/A | |
 LENSAR, Inc. NASDAQ:LNSR | 10.70M | 45.9% | 83.3% | N/A | |
 Perspective Therapeutics, Inc. AMEX:CATX | 7.53M | 12.7% | 150.1% | 76.3% | |
 Neuronetics, Inc. NASDAQ:STIM | 1.87M | -13.9% | 15.3% | 16.5% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 145.31M | 70.4% | N/A | 38.1% |
TriSalus Life Sciences, Inc. Fair Value Envelope
Related Guides
Continue your TLSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.